

Stereotactic Body Radiation Therapy For The Treatment of Localized Prostate Cancer In Men With Underlying Inflammatory Bowel Disease

Jonathan W. Lischalk (✉ Jonathan.Lischalk@nyulangone.org)

Perlmutter Cancer Center at New York University Langone Hospital

Seth Blacksburg

Lenox Hill Hospital

Christopher Mendez

NYU Langone Health <https://orcid.org/0000-0001-5439-3901>

Michael Repka

NYU Langone Health

Astrid Sanchez

NYU Langone Health

Todd Carpenter

NYU Langone Health

Matthew Witten

NYU Langone Health

Jules E. Garbus

New York University Long Island School of Medicine

Andrew Evans

New York University School of Medicine

Sean Collins

Georgetown University Medical Center

Aaron Katz

New York University Long Island School of Medicine

Jonathan Haas

NYU Langone Health

Research

Keywords: Prostate, stereotactic body radiation therapy, inflammatory bowel disease

Posted Date: June 18th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-592369/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Radiation Oncology on July 9th, 2021. See the published version at <https://doi.org/10.1186/s13014-021-01850-1>.

Abstract

Background

Historically, IBD has been thought to increase the underlying risk of radiation related toxicity in the treatment of prostate cancer. In the modern era, contemporary radiation planning and delivery may mitigate radiation related toxicity in this theoretically high-risk cohort. This is the first manuscript to report clinical outcomes for men diagnosed with prostate cancer and underlying IBD curatively treated with stereotactic body radiation therapy (SBRT).

Methods

A large institutional database of patients (n = 4,245) treated with SBRT for adenocarcinoma of the prostate was interrogated to identify patients who were diagnosed with underlying IBD prior to treatment. All patients were treated with SBRT over five treatment fractions using a robotic radiosurgical platform and fiducial tracking. Baseline IBD characteristics including IBD subtype, pre-SBRT IBD medications, and EPIC bowel questionnaires were reviewed for the IBD cohort. Acute and late toxicity was evaluated using the CTCAE version 5.0.

Results

A total of 31 patients were identified who had underlying IBD prior to SBRT for the curative treatment of prostate cancer. The majority (n = 18) were diagnosed with ulcerative colitis and the majority were being treated local steroid suppositories for IBD. No biochemical relapses were observed in the IBD cohort with early follow up. High-grade acute and late toxicities were rare (n = 1, grade 3 proctitis) with a median time to any GI toxicity of 22 months. Hemorrhoidal flare was the most common low-grade toxicity observed (n = 3).

Conclusion

To date, this is one of the largest groups of patients with IBD treated safely and effectively with radiation for prostate cancer and the only review of patients treated with SBRT. Caution is warranted when delivering therapeutic radiation to patients with IBD, however modern radiation techniques appear to have mitigated the risk of GI side effects.

Background

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disorder that affects over one million individuals in the United States and is increasing in incidence ^{1,2}. The illness is separated into two distinct subtypes: (1) Crohn's disease (CD), and (2) ulcerative colitis (UC). Each type carries discrete anatomical and pathophysiological characteristics, but both can fundamentally worsen baseline bowel function ³. Moreover, IBD carries an increased risk of secondary malignancies ⁴. As such, notable efforts

have been made to minimize exposure of patients diagnosed with IBD to ionizing radiation even those used for diagnostic purposes⁵⁻⁸.

Autoimmune disorders including IBD are thought to lead to synergistic increases in toxicity when combined with therapeutic radiation, and great caution has been historically exercised with their combination. A systemic review of the literature identified only eight trials with a total of 144 patients diagnosed with underlying IBD and treated with pelvic radiotherapy⁹. Small case studies have warned against the use of radiation in cases of underlying IBD, and have labeled therapeutic radiation as a “relative contraindication”^{10,11}. Older data from Massachusetts General Hospital (MGH) reported nearly a 50% rate of “severe toxicity” in 28 patients identified from 1970 to 1999 who were treated with abdominopelvic radiotherapy for a variety of malignancies including seven patients with prostate cancer¹². Such late toxicity included 29% of patients requiring surgical intervention or hospitalization. Therefore, in cases such as prostate cancer where definitive treatment options exist outside of radiation, such alternative local therapies have thus been prudently advocated¹². It is important to note that anti-inflammatories used to manage IBD can also increase the risk of wound dehiscence and infection following surgery, thus their peri-operative discontinuation may in and of itself flair underlying IBD¹³.

In the current era, the toxicity risk with radiation appears to be lower if patients are carefully selected and new radiation modalities are utilized¹⁴⁻¹⁹. Stereotactic body radiation therapy (SBRT) has been demonstrated to be clinically effective and has become a ubiquitous option for selected men with localized adenocarcinoma of the prostate²⁰. However, no literature exists regarding the acute and late toxicity for men with underlying IBD treated with SBRT for prostate cancer. It is reasonable to hypothesize that SBRT using contemporary imaging, advanced treatment planning, and precise radiation delivery could mitigate radiation-related toxicity even in this theoretically higher risk cohort.

In this manuscript, we describe our large institutional experience, spanning nearly a decade, and review the clinical outcomes of patients diagnosed with underlying IBD and subsequently treated with SBRT for localized prostate cancer.

Methods

Patient eligibility

This single institutional review of patients treated with SBRT for prostate cancer was approved by the local Institutional Review Board (Study # 00001269). All patients were evaluated by a radiation oncologist and deemed appropriate for definitive SBRT. All patients underwent pre-treatment diagnostic tests including clinical examination, PSA, and transrectal ultrasound-guided biopsy. Patients were categorized into D’Amico risk group classifications. All patients underwent placement of fiducial markers in the prostate approximately one week prior to simulation. Fiducial markers were utilized for inter- and intra-fractional image guidance using a robotic radiosurgical platform. Patient IBD history was reviewed

in detail to determine the diagnosed subtype of disease as UC, CD, or IBD not otherwise specified. Pre-SBRT IBD treatment (e.g. suppositories, systemic steroids, etc.) was reviewed and documented (Table 2).

Table 2
Inflammatory bowel disease details

IBD subtype	n	%
Ulcerative colitis	18	58
Crohn's disease	11	36
Not otherwise specified	2	6
Pre-SBRT IBD medication		
Mesalamine	11	36
Sulphasalazine	4	13
Prednisone	2	6
Hydroxychloroquine	1	3
Other*	6	19
None	7	23
Blood thinner use		
Coumadin	3	10
Aspirin	2	6
*azathioprine, balsalazide, budesonide, methotrexate, solasodine		

Simulation, planning, and treatment delivery

All patients underwent computed tomography (CT)-based radiation treatment planning simulation (GE Optima 580). An MRI of the prostate was also obtained in the majority of cases at the time of simulation and fused with the primary simulation CT scan at the level of the fiducials to assist in target volume delineation with particular attention paid to the prostate and rectal interface. Patients were recommended enema usage prior to simulation and delivery of each treatment fraction. Target volume contours were generated using previously defined definitions. Nodal radiation was incorporated for those patients deemed to be at high risk for nodal involvement. Organs at risk (OAR) were contoured and included rectosigmoid, bladder, penile bulb, small bowel, and femoral heads.

Clinical target volume included the entire prostate and proximal seminal vesicles. A 5 mm isometric expansion of the CTV was created with a tighter, 3 mm, posterior margin to form the PTV. Dose calculations and planning optimization were performed using Accuray MultiPlan software. Beam angles were created to optimize target volume coverage and minimize exposure of normal structures, with

particular attention paid to the rectum. Dosimetric constraints for the aforementioned normal structures were utilized based on institutional standards. All patients were treated using stereotactic body radiation therapy delivered over five treatment fractions. Treatments were delivered using a robotic radiosurgical platform with prostate motion accounted for in the x-, y-, and z-plane. All patients received intra-rectal amifostine in effort to reduce the risk of radiation-related GI toxicity. Finally, a small number of patients underwent pre-treatment rectal spacer placement, though the majority of patients were treated in an era prior to widespread spacer use.

Follow-up

Acute toxicity was defined as that occurring within 90 days of treatment completion. Late toxicity was defined as that occurring greater than 90 days after radiotherapy completion. Toxicity was reported using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Patients were followed using serial PSA and clinical examination commonly at 3-month intervals for the first year and subsequently every 6 to 12 months thereafter. Toxicity was measured from completion of SBRT. Patients who underwent EPIC questionnaires pre and post SBRT were reviewed with a specific focus on bowel habits.

Statistical analysis

Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) version 24 (Armonk, NY). The IBD and non-IBD cohort demographic, cancer, and treatment data were compared using Chi-Square analysis.

Results

Patient and tumor characteristics

In this single institutional retrospective review, we identified 4,245 patient who were treated with definitive SBRT for localized prostate cancer from 2012 to 2020. Of this cohort, 31 patients (1%) were found to have an underlying diagnosis of IBD prior to undergoing SBRT. The majority of patients in the IBD cohort were between the ages of 60 and 70 years, and there was no significant difference ($p = 0.58$) in the age distribution between the IBD and non-IBD patients when analyzed as a continuous variable. The majority of IBD patients had an excellent documented ECOG performance status of 1 ($n = 18, 58\%$). Androgen deprivation therapy was utilized as a component of treatment in the minority of patients ($n = 7, 23\%$), and was not significantly different relative to the non-IBD cohort.

Within the IBD cohort, the prostate cancer risk grouping was as follows: low ($n = 8, 26\%$), intermediate ($n = 17, 55\%$), and high ($n = 6, 19\%$). Pre-treatment PSA was < 10 ng/mL in the majority of patients ($n = 24, 77\%$). There were no patients found to have locally advanced (i.e. clinical stage T3-4) disease and nearly half were diagnosed with pathologic grade group 2 cancer ($n = 13, 42\%$). There was no statistically significant difference identified between the IBD and non-IBD cohorts from a PSA ($p = 0.09$), clinical stage ($p = 0.65$), pathological grade group ($p = 0.83$), or overall risk group standpoint ($p = 0.97$). Patient and tumor characteristics are listed in Table 1.

Table 1
Patient tumor and characteristics

	IBD		No IBD		p-value
	n	%	n	%	
Age					
< 60 years	4	12.90%	860	20.41%	0.58
60–70 years	15	48.40%	1840	43.66%	
> 70 years	12	38.70%	1514	35.93%	
ECOG					
0	18	58.07%			
1	2	6.45%			
No score	11	35.48%			
PSA (mg/mL)					
< 10	24	77.42%	3281	77.86%	0.09
10–20	3	9.68%	725	17.20%	
> 20	4	12.90%	208	4.94%	
AJCC 8-Edition Stage					
T1	24	77.42%	3436	81.54%	0.65
T2	7	22.58%	733	17.39%	
T3-T4	0	0.00%	45	1.07%	
Grade Group					
1	9	29.03%	1314	31.18%	0.83
2	13	41.94%	1436	34.08%	
3	4	12.90%	833	19.77%	
4	3	9.68%	418	9.92%	
5	2	6.45%	213	5.05%	
Risk Group					
Low	8	25.81%	1066	25.30%	0.97
Intermediate	17	54.84%	2392	56.76%	

	IBD		No IBD		
High	6	19.35%	756	17.94%	
ADT					
Yes	7	22.58%	943	22.38%	0.98
No	24	77.42%	3271	77.62%	

Inflammatory bowel disease diagnosis and severity prior to treatment

Inflammatory bowel disease subtype was most commonly UC (n = 18, 58%) followed by CD (n = 11, 26%) with the remainder of patients having IBD not otherwise specified (n = 2, 16%). The majority of patients (n = 24, 77%) with IBD received medical treatment prior to undergoing radiotherapy. The majority of patients received treatment with local steroidal suppositories (n = 15, 48%). However, systemic treatment was prescribed in nine patients (29%) and included prednisone, hydroxychloroquine, and methotrexate amongst other medications. Anticoagulation use was not common in the IBD cohort (n = 5, 16%). Nearly half of patients (n = 14) within the IBD cohort completed EPIC questionnaires prior to SBRT, which were interrogated for HRQOL bowel domain summary and bowel subscales. Overall, pretreatment HRQOL bowel domain summary scores for the IBD cohort were good with a median score of 90.18 (range, 37.50 to 100.0). The median pre-SBRT domain-specific HRQOL subscales for bowel function and bother were 94.64 (range, 46.43–100.00) and 91.07 (range, 28.57–100.00), respectively. Inflammatory bowel disease and EPIC questionnaire data details are shown in Tables 2 and 3, respectively.

Table 3
EPIC Questionnaire

	Baseline (n = 14)	1 month (n = 5)	3–4 months (n = 4)	6–9 months (n = 4)
HRQOL Bowel domain summary				
Median	90.18	71.43	64.29	82.14
Mean	84.18	58.93	62.05	75.45
Range	37.50–100.00	7.14–94.64	23.21–96.43	41.07–96.43
Domain-specific HRQOL subscales				
Function				
Median	94.64	71.43	67.86	80.36
Mean	86.99	59.29	63.39	76.79
Range	46.43–100.00	10.71–89.29	21.43–96.43	50.00–96.43
Bother				
Median	91.07	71.43	60.71	83.93
Mean	81.38	58.57	60.71	74.11
Range	28.57–100.00	3.57–100.00	25.00–96.43	32.14–96.43

Treatment and dosimetric characteristics

All patients were treated with SBRT to the prostate and proximal seminal vesicles. However, two patients within the IBD group received supplemental pelvic nodal irradiation followed by a prostate and seminal vesicle SBRT boost due to their high-risk disease. The majority of patients were treated to a total dose of 3500 cGy in five fractions (n = 26, 84%). Of the remaining patients, three were treated to 36.25 cGy and two patients received a prostate and seminal vesicle boost (2100 cGy and 1950 cGy each in 3 fractions) after nodal irradiation to 4500 cGy in 25 fractions. Most frequently, treatments were delivered on a consecutive day schedule (n = 29, 94%). Only two patients within the IBD group underwent pre-treatment polyethylene glycol gel spacer placement. The remaining patients were treated with amifostine as a rectal protectant.

Dosimetric analysis of the IBD cohort (sans pelvic lymph nodes) was performed with particular attention paid to rectal dosimetry for the majority of patients (n = 27). Target volume coverage in the IBD cohort was excellent with CTV and PTV prescription coverage of 100% and 97%, respectively. Median prescription isodose line was 84% (range, 83–87.5%). Median maximum point dose to the rectum was 3754 cGy with a median rectal V3600 cGy of 0.29 cc. The remaining radiation treatment and dosimetric details are listed in Table 4.

Table 4
Treatment and dosimetry results

	IBD		No IBD		p-value
	n	%	n	%	
Radiation dose					
3500 cGy in 5 fractions	26	84	3139	74	0.46
3625 cGy in 5 fractions	3	10	537	13	
Whole pelvis					
2100 cGy in 3 fractions	1	3	422	10	
1950 cGy in 3 fractions	1	3	86	2	
Dosimetric parameter	Mean	Median	Range		
Target coverage					
CTV VRx (%)	99.0	99.9	99.4–100		
PTV VRx (%)	96.6	96.5	95.0–99.5		
IDL (%)	84.1	84	83–87.5		
Max dose (cGy)	4182.13	4167	4117.65–4216.87		
Rectum Max (cGy)	3777.8	3753.5	3604–3919.29		
Rectum V37.8 (%)	0.1	0	0–0.3		
V37.8 cc (cc)	0.04	0	0–0.20		
Rectum V33.9 (%)	5.16	4.7	0.8–12.6		
V33.9 cc (cc)	2.73	2	0.55–9.03		
Rectum V29 (%)	14.68	14.6	5.6–25.3		
V29 cc (cc)	7.69	6.32	3.08–18.04		
Rectum V19.2 (%)	37.42	37.3	19.9–55.8		
V19.2 cc (cc)	18.84	15.72	9.18–34.16		
Rectum V36 (cc)	0.35	0.29	0.01–0.88		
Large Bowel Max (cGy)	2566.18	2601	1239.47–3688.99		
Small Bowel Max (cGy)	1089.82	1089.82	956–1223.64		

Oncologic and toxicity outcomes

Overall, excellent short-term oncologic outcomes were observed regardless of prostate cancer risk group classification in those men diagnosed with underlying IBD. With a median follow up of 22 months, no

patients within the IBD cohort were found to have a Phoenix definition biochemical failure. The median and mean PSA nadir for those with IBD was found to be 0.35 ng/mL and 0.76 ng/mL, respectively.

Overall, high-grade acute and late gastrointestinal toxicity was extremely rare (n = 1). Median time to any GI toxicity following SBRT was 22-months. One patient developed grade 3 proctitis requiring hospital management less than 1 month following SBRT. Two additional patients developed grade 2 proctitis requiring outpatient medical management at 22- and 29-months. Hemorrhoids, including hemorrhoidal hemorrhage, were the remaining observed toxicities (n = 3). Toxicity details are illustrated in Table 5. A very small number of patients had EPIC questionnaires available for interrogation following SBRT. Although difficult to generalize given the small patient numbers, bowel quality of life appears to decline 1 month following SBRT with gradual improvements seen at 3 to 4 months and 6 to 9 months (Table 3).

Table 5
Gastrointestinal toxicity (CTCAE version 5.0)

Toxicity	Time to toxicity (months)	IBD subtype	Risk group	Total dose (cGy)	IDL (%)	Rectal D _{max} (cGy)	Pre-SBRT IBD meds
Grade 3 proctitis	< 1	UC	Int.	3500	84	3656	Mesalamine
Grade 2 proctitis	29	UC	Low	3500	85	3852	Prednisone
Grade 2 proctitis	22	UC	Int.	3500	83	3860	Mesalamine
Grade 2 hemorrhoids	10	CD	High	3500	86	3839	Methotrexate
Grade 1 rectal hemorrhage	< 1	CD	High	3500	86	3839	Methotrexate
Grade 1 hemorrhoids	22	UC	Int.	3500	83	3860	Mesalamine

All patients who developed toxicity were treated to a total dose of 3500 cGy in five fractions. The documented median rectal point dose maximum was 3853 cGy in patients who developed toxicity, which was slightly higher than that of the entire IBD cohort (3754 cGy). Interestingly, the two patients treated with pelvic nodal irradiation were not found to have toxicity. Those patients who underwent pre-treatment rectal spacer placement also did not develop toxicity. Of note, all patients who developed toxicity were receiving IBD medical treatment prior to SBRT often with systemic medication.

Discussion

The pathophysiological mechanism of radiation-induced damage in IBD remains nebulous. It may be a multifactorial process involving underlying IBD sensitivities to vascular damage, inherently altered DNA repair pathways, and a susceptibility to excessive free radical damage²¹⁻²³. Conversely, radiation has

well known immunomodulatory properties and can be notably cytotoxic to immune cells even in low doses yielding anti-inflammatory effects²⁴⁻²⁶. The immunosuppressive effect of radiation has been recently explored for the treatment of COVID-19-related pneumonia with mixed results²⁷. Thus, it is fair to ask whether radiation might suppress the dysregulated and hyperactive mucosal immune response in the rectum leading to improved symptomatology, which is intriguingly what was observed by a Gestaut et al.¹⁶.

Gestaut et al. reported a group of 18 patients with exclusively prostate cancer treated with a variety of radiation modalities including three-dimensional conventional radiation therapy (3DCRT), intensity modulated radiation therapy (IMRT), and low dose rate brachytherapy (12 patients received EBRT). The majority of patients (79%) required IBD medication prior to and during radiation treatment. Similar to our study, remarkably low GI toxicity was observed with no instances of grade 3 + toxicity identified. Of note, grade 2 proctitis was observed more frequently following 3DCRT, prompting the authors to advocate for the use of more conformal radiation techniques (e.g. IMRT). The use of “specialized” radiation techniques to minimize late toxicity was also observed in the aforementioned MGH publication¹². Interestingly, the overall cohort demonstrated decreased grade 1 diarrhea immediately following radiation, and the authors postulate this may be a result of radiation’s effect in mitigating IBD symptoms, at least in the acute setting.

Excess GI toxicity risk in patients with IBD is difficult to compare to a non-IBD cohort due to limited patient numbers. However, Murphy et al. reviewed 16 patients with underlying IBD who were treated with EBRT for prostate cancer and attempted to identify case controls without IBD to delineate a comparative risk profile¹⁷. Interestingly, no difference in grade 2 + toxicity was identified between patients with IBD and case controls. Late grade 2 toxicity was low at 10% (vs. 17% in Gestaut et al.), which could be explained by the lower numbers of patients who received concurrent IBD medication, (47% versus 79%) perhaps indicative of the lower severity of underlying IBD in the Murphy et al. patient cohort¹⁶.

In a unique publication, Feagins et al. reviewed a cohort entirely of IBD patients who did or did not receive radiation for prostate cancer treatment - distinct from all other publications, which reviewed radiation patients who did or did not have IBD. Veterans Administration data was reviewed from 1996 to 2015 of patients treated for prostate cancer with radiation versus a non-radiation modality¹⁵. Baseline characteristics between the radiation and non-radiation cohorts did not appear to be different. However, there was a 2-fold higher rate of IBD flares within the first year after radiation relative to those patients who did not receive radiotherapy as primary treatment. Nevertheless, there were no differences in high-grade toxicities (i.e. hospitalization or surgeries). The use of “IBD flare” as a metric for toxicity in this trial is unique - only Annede et al. published similarly. Whether IBD flares represent the equivalent of a low-grade CTCAE toxicity is difficult to establish, but highlights the importance of comparing apples to apples across publications with respect to toxicity metrics.

Attempts to exploit the inverse square law to minimize rectal toxicity using I-125 LDR brachytherapy was reported by Pai et al.²⁸. A total of 13 patients with IBD received I-125 implants and a markedly elevated

rate of grade 3 + toxicity was observed at 23% and 15% for acute and late toxicity, respectively. Importantly, all patients who developed high-grade late toxicity underwent rectal biopsies shortly after brachytherapy implant. Similar high-grade toxicity was observed in patients with IBD treated with EBRT for colorectal cancer in the peri-operative setting²⁹. These studies allude to an augmented toxicity risk with surgical manipulation of the pelvis in IBD cases following radiation, and highlight the importance of avoiding elective rectal interventions shortly after radiotherapy regardless of the presence of underlying bowel disease.

Literature for more heterogeneous groups of malignancies have highlighted several additional risk factors associated with toxicity including concurrent chemotherapy use and IBD location. Annede et al. reported a diverse group of patients with pelvic malignancies and IBD (12 of 28 with prostate cancer) treated with radiation from 1989 to 2015³⁰. External beam radiotherapy (primarily older 2D techniques) was delivered to a median dose of 53 Gy. Of note, no patients had “active IBD” at baseline in this study. Only rectal IBD anatomical location was significantly correlated with IBD exacerbation within 6 months after radiation. With a median follow up of nearly 6 years, grade 3 + GI toxicity rate was 11% and 4% for acute and late toxicity, respectively. Johns Hopkins Hospital reported on 24 patients with IBD who underwent primarily chemoradiation with conventional techniques for a heterogeneous group of malignancies (only one prostate cancer). High-grade toxicity (3+) was reported at 21% and 8% for acute and late toxicity, respectively, with concurrent chemotherapy being the primary driver of toxicity.

Many of the aforementioned patients were treated with antiquated radiation techniques in an era when 3D planning did not exist and modern image guided radiation therapy (IGRT) had yet to be developed. Systemic review of the literature in this setting of a heterogeneous cancer cohort and EBRT treatment technique estimated the mean rate of acute and late grade 3 + GI toxicity to be quite high at 20% (range: 11 to 27%) and 15% (range: 0 to 23%), respectively⁹. Contemporary radiation incorporates detailed imaging including prostate MRI, exquisitely conformal radiation planning, and inter- and intra-fractional IGRT. Such improvements have led to decreases in radiation toxicity without a detriment in oncologic outcome³¹. The most notable modern advancement from a rectal toxicity standpoint is the placement of a polyethylene glycol-based gel that creates an artificial space between the posterior aspect of the prostate and anterior aspect of the rectum. Placement of hydrogel spacers has consistently demonstrated superior dosimetry across nearly all dose volume parameters, and has translated into low rates of GI toxicity and excellent patient reported quality of life outcomes³²⁻³⁷. For patients with underlying IBD, such dramatic improvements in rectal dose and toxicity may be a panacea. In our particular IBD cohort, two patients underwent rectal spacer placement, and neither developed gastrointestinal toxicity.

Limitations of the present study include its retrospective nature, relatively short median follow up, and limited patient numbers, which is a consequence of the rarity of the clinical situation. Nevertheless, this is one of the largest cohorts ever reported of patients with IBD treated with modern radiation, the most detailed and homogenous from a radiation technique standpoint, and the only report detailing outcomes

following SBRT. Caution is warranted and careful selection of patients appears to be crucial. If possible, treatment should be avoided during active IBD flares, particularly if localized to the rectum, and patients should be well managed medically prior to treatment. Strong consideration should be made for use of rectal spacers in effort to minimize rectal exposure to radiation. Conformal radiation with rigorous IGRT should be utilized and following radiation elective biopsies of the rectum should be avoided at all costs. Nevertheless, contrary to historical lore, prostate radiotherapy in patients with underlying IBD does not appear to be as toxic in the modern era.

Conclusion

Caution is warranted when delivering therapeutic radiation to patients with IBD; however, modern radiation techniques appear to have mitigated the risk of GI side effects. To date, this is one of the largest groups of patients with IBD treated with radiation for prostate cancer and the only review of patients treated with SBRT. Delivery of 5-fraction SBRT using a non-coplanar robotic platform with tight posterior margins result in low rates of gastrointestinal toxicity with no significant detriment on oncologic outcome.

Abbreviations

IBD – Inflammatory bowel disease

CD – Crohn's disease

UC – Ulcerative colitis

MGH – Massachusetts General Hospital

SBRT – Stereotactic body radiation therapy

PSA – Prostate specific antigen

CT – Computed tomography

MRI – Magnetic resonance imaging

OAR – Organs at risk

CTV – Clinical target volume

PTV – Planning target volume

GI – Gastrointestinal

CTCAE – Common Terminology Criteria for Adverse Events

EPIC – The Expanded Prostate Cancer Index Composite

SPSS – Statistical Package for Social Sciences

ECOG – Eastern Cooperative Oncology Group

ADT – Androgen deprivation therapy

HRQOL – Health Related Quality of Life

cGy – centigray

DNA – Deoxyribonucleic acid

3DCRT – Three-dimensional conventional radiation therapy

IMRT – Intensity modulated radiation therapy

EBRT – External beam radiation therapy

LDR – Low dose rate

IGRT – Image guided radiation therapy

Declarations

Ethics approval and consent to participate

This single institutional review of patients treated with SBRT for prostate cancer was approved by the local Institutional Review Board (Study # 00001269).

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

JWL and SB are paid speakers for Accuray. The remaining authors have no competing interests.

Funding

Accuray research grant

Authors' contributions

JWL, SB, CM, MR, AS, TC, MW, JEG, AE, AK, SC, and JH all contributed to study concept, design, and/or acquisition of data. JWL, SB, CM, AS, and JH completed the data collection. JWL, SB, CM, AS, MR, and JH contributed to the data analysis. JWL, SB, CM, MR, AS, TC, MW, JEG, AE, AK, SC, and JH was responsible for drafting the manuscript. All authors contributed to revising and giving final approval to the manuscript. All authors agree to be accountable for all aspects of the work including accuracy and integrity.

Acknowledgements

Not applicable

References

1. Abraham C, Cho JH. Inflammatory Bowel Disease. *N Engl J Med*. 2009;361(21):2066–78. doi:10.1056/NEJMra0804647.
2. Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease. *Gastroenterol Clin North Am*. 2002;31(1):1–20. doi:10.1016/s0889-8553(01)00002-4.
3. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology*. 2011;140(6):1785–94. doi:10.1053/j.gastro.2011.01.055.
4. Bernstein CN, Blanchard JF, Kliwer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. *Cancer*. 2001;91(4):854–862. doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z
5. Civitelli F, Casciani E, Maccioni F, et al. Use of Imaging Techniques in Inflammatory Bowel Diseases That Minimize Radiation Exposure. *Curr Gastroenterol Rep*. 2015;17(7):28. doi:10.1007/s11894-015-0448-y.
6. Englund H, Lidén KK, Lind T, Sundström T, Karling P. Radiation exposure in patients with inflammatory bowel disease and irritable bowel syndrome in the years 2001–2011. *Scand J Gastroenterol*. 2017;52(3):300–5. doi:10.1080/00365521.2016.1252945.
7. Grand DJ, Harris A, Shapiro J, et al. Risk factors for radiation exposure in newly diagnosed IBD patients. *Abdom Radiol N Y*. 2016;41(7):1363–9. doi:10.1007/s00261-016-0650-x.
8. Zakeri N, Pollok RCG. Diagnostic imaging and radiation exposure in inflammatory bowel disease. *World J Gastroenterol*. 2016;22(7):2165–78. doi:10.3748/wjg.v22.i7.2165.
9. Tromp D, Christie DRH. Acute and Late Bowel Toxicity in Radiotherapy Patients with Inflammatory Bowel Disease: A Systematic Review. *Clin Oncol R Coll Radiol G B*. 2015;27(9):536–41. doi:10.1016/j.clon.2015.05.001.
10. Schofield PF, Holden D, Carr ND. Bowel disease after radiotherapy. *J R Soc Med*. 1983;76(6):463–6.

11. Hoffman M, Kalter C, Roberts WS, Cavanagh D. Early cervical cancer coexistent with idiopathic inflammatory bowel disease. *South Med J*. 1989;82(7):905–6. doi:10.1097/00007611-198907000-00027.
12. Willett CG, Ooi CJ, Zietman AL, et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. *Int J Radiat Oncol Biol Phys*. 2000;46(4):995–8. doi:10.1016/s0360-3016(99)00374-0.
13. Busti AJ, Hooper JS, Amaya CJ, Kazi S. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. *Pharmacotherapy*. 2005;25(11):1566–91. doi:10.1592/phco.2005.25.11.1566.
14. Song DY, Lawrie WT, Abrams RA, et al. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. *Int J Radiat Oncol*. 2001;51(2):455–9. doi:10.1016/S0360-3016(01)01629-7.
15. Feagins LA, Kim J, Chandrakumaran A, et al. Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy. *Inflamm Bowel Dis*. 2020;26(5):728–33. doi:10.1093/ibd/izz175.
16. Gestaut MM, Swanson GP. Long term clinical toxicity of radiation therapy in prostate cancer patients with Inflammatory Bowel Disease. *Rep Pract Oncol Radiother J Gt Cancer Cent Poznan Pol Soc Radiat Oncol*. 2017;22(1):77–82. doi:10.1016/j.rpor.2016.10.005.
17. Murphy CT, Heller S, Ruth K, et al. Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. *Pract Radiat Oncol*. 2015;5(3):e215–22. doi:10.1016/j.ppro.2014.09.004.
18. White EC, Murphy JD, Chang DT, Koong AC. Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy. *Am J Clin Oncol*. 2015;38(6):564–9. doi:10.1097/COC.0000000000000010.
19. Jmour O, Pellat A, Colson-Durand L, et al. [Radiation therapy in patients with inflammatory bowel disease. A review]. *Bull Cancer (Paris)*. 2018;105(5):517–22. doi:10.1016/j.bulcan.2018.02.005.
20. King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. *Radiother Oncol J Eur Soc Ther Radiol Oncol*. 2013;109(2):217–21. doi:10.1016/j.radonc.2013.08.030.
21. Kk S, Fm P, C B, Fl M. R P. Deficient DNA repair in chronic ulcerative colitis. *Cancer Detect Prev*. 1997;21(6):540–5.
22. Korzenik JR. IBD: A Vascular Disorder? The Case for Heparin Therapy. *Inflamm Bowel Dis*. 1997;3(2):87–94.
23. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. *Lancet Lond Engl*. 1994;344(8926):859–61. doi:10.1016/s0140-6736(94)92831-2.
24. Trott KR. Therapeutic effects of low radiation doses. *Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al*. 1994;170(1):1–12.

25. Trott KR, Kamprad F. Radiobiological mechanisms of anti-inflammatory radiotherapy. *Radiother Oncol J Eur Soc Ther Radiol Oncol*. 1999;51(3):197–203. doi:10.1016/s0167-8140(99)00066-3.
26. Roedel F, Kley N, Beuscher HU, et al. Anti-inflammatory effect of low-dose X-irradiation and the involvement of a TGF-beta1-induced down-regulation of leukocyte/endothelial cell adhesion. *Int J Radiat Biol*. 2002;78(8):711–9. doi:10.1080/09553000210137671.
27. Hess CB, Nasti TH, Dhere V, et al. Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia. *Int J Radiat Oncol Biol Phys* Published online December 16, 2020. doi:10.1016/j.ijrobp.2020.12.011.
28. Pai HH, Keyes M, Morris WJ, Christie J. Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease. *Brachytherapy*. 2013;12(2):126–33. doi:10.1016/j.brachy.2012.04.008.
29. Chang BW, Kumar AMS, Koyfman SA, Kalady M, Lavery I, Abdel-Wahab M. Radiation therapy in patients with inflammatory bowel disease and colorectal cancer: risks and benefits. *Int J Colorectal Dis*. 2015;30(3):403–8. doi:10.1007/s00384-014-2103-8.
30. Annede P, Seisen T, Klotz C, et al. Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy. *J Gastrointest Oncol*. 2017;8(1):173–9. doi:10.21037/jgo.2017.01.13.
31. Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2012;84(1):125–9. doi:10.1016/j.ijrobp.2011.11.047.
32. Hedrick SG, Fagundes M, Robison B, et al. A comparison between hydrogel spacer and endorectal balloon: An analysis of intrafraction prostate motion during proton therapy. *J Appl Clin Med Phys*. 2017;18(2):106–12. doi:10.1002/acm2.12051.
33. Song DY, Herfarth KK, Uhl M, et al. A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. *Int J Radiat Oncol Biol Phys*. 2013;87(1):81–7. doi:10.1016/j.ijrobp.2012.12.019.
34. Susil RC, McNutt TR, DeWeese TL, Song D. Effects of prostate-rectum separation on rectal dose from external beam radiotherapy. *Int J Radiat Oncol Biol Phys*. 2010;76(4):1251–8. doi:10.1016/j.ijrobp.2009.07.1679.
35. Chao M, Ho H, Chan Y, et al. Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy. *BJU Int*. 2018;122(3):427–33. doi:10.1111/bju.14192.
36. Whalley D, Hruby G, Alfieri F, Kneebone A, Eade T. SpaceOAR Hydrogel in Dose-escalated Prostate Cancer Radiotherapy: Rectal Dosimetry and Late Toxicity. *Clin Oncol R Coll Radiol G B*. 2016;28(10):e148–54. doi:10.1016/j.clon.2016.05.005.
37. Chao M, Lim Joon D, Khoo V, et al. The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial. *World J Urol*. 2019;37(6):1111–6. doi:10.1007/s00345-018-2502-5.